PaxMedica Completes HAT-301 Registrational Trial for PAX-101
June 01, 2023 08:00 ET
|
PaxMedica, Inc.
HAT-301 is the Pivotal Efficacy Study to Support Upcoming NDA Filing Top Line Results Planned for Release in July 2023 TARRYTOWN, NY, June 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –...
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
May 15, 2023 16:13 ET
|
PaxMedica, Inc.
TARRYTOWN, NY, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic...
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month
April 19, 2023 08:30 ET
|
PaxMedica, Inc.
Broadcasting Live on Wednesday April 19th at 3:45 PM ET TARRYTOWN, NY, April 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage...
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results
March 29, 2023 19:21 ET
|
PaxMedica, Inc.
-Phase 3 Results for HAT-301 Retrospective Trial Expected in Second Half 2023- Fourth Quarter 2022 Highlights Initiated Phase 3 Clinical Program to Advance PAX-101 Towards FDA...
PaxMedica Holds Meeting of Scientific Advisory Board
March 20, 2023 08:00 ET
|
PaxMedica, Inc.
Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S. TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical...
PaxMedica Releases 2022 Shareholder Letter
February 15, 2023 07:30 ET
|
PaxMedica, Inc.
Company Anticipates Multiple Milestones in Next 12-24 Months TARRYTOWN, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage...
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
February 03, 2023 08:00 ET
|
PaxMedica, Inc.
Additional Capital Will Help Fund Development of PAX-101 TARRYTOWN, NY, Feb. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical...
PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event
January 20, 2023 13:31 ET
|
PaxMedica, Inc.
Presentation on Thursday, January 26th, 2023 at 1:30 PM EST TARRYTOWN, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical...
PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com
December 14, 2022 08:00 ET
|
PaxMedica, Inc.
Update Offers More Comprehensive Understanding of PaxMedica’s Focus, Process and Progress Tarrytown, NY, Dec. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a...
PaxMedica to Present at the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 22, 2022 08:00 ET
|
PaxMedica, Inc.
TARRYTOWN, NY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic...